Pharmaceutical - Antibiotics and Infectious diseases

Filter

Popular Filters

76 to 100 of 220 results

Four medicines recommended for approval by EMA/CHMP

Four medicines recommended for approval by EMA/CHMP

22-12-2013

Following regular monthly meeting of the European Medicines Agency’s Committee for Medicinal Products…

AlconAntibiotics and Infectious diseasesComtriqDermatologicalsEuropeGaldermaJanssen-CilagJohnson & JohnsonMirvasoNovartisOncologyOphthalmicsPharmaceuticalRegulationSirturoTMC Pharma Services

New Ph III data support early 2014 filing for Cubist’s ceftolozane/tazobactam

New Ph III data support early 2014 filing for Cubist’s ceftolozane/tazobactam

17-12-2013

US drugmaker Cubist Pharmaceuticals saw its shares jump 8.3% to $68 in premarket trading yesterday, when…

Antibiotics and Infectious diseasesceftolozoneCubist PharmaceuticalsEuropeNorth AmericaPharmaceuticalRegulationResearchtazobactam

AbbVie reports 96% response in Phase III hepatitis C study

AbbVie reports 96% response in Phase III hepatitis C study

10-12-2013

US drugmaker AbbVie (NYSE: ABBV)has released Phase III results for the investigational three direct-acting-antiviral…

AbbVieAnti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

GSK’s Synflorix gets additional indication in Europe

GSK’s Synflorix gets additional indication in Europe

05-12-2013

The European Commission has granted marketing authorization for an additional indication for UK pharma…

Antibiotics and Infectious diseasesEuropeGlaxoSmithKlinePharmaceuticalRegulationSynflorix

IFPMA and the Global Fund collaborate to help protect patients from fake medicines

05-12-2013

The International Federation of Pharmaceutical Manufacturers and Associations and the Global Fund to…

Anti-viralsAntibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalRegulationTropical diseases

The Medicines Company acquires antibiotics maker Rempex Pharma

04-12-2013

USA-based The Medicines Company has acquired Rempex Pharmaceuticals, a company with multiple potential…

Antibiotics and Infectious diseasesMergers & AcquisitionsPharmaceuticalRempex PharmaceuticalsThe Medicines Company

Global Fund-proposed shake-up to drug pricing framework risks middle-income countries paying more, says MSF

Global Fund-proposed shake-up to drug pricing framework risks middle-income countries paying more, says MSF

04-12-2013

Ahead of the Global Fund replenishment conference in Washington DC this week, international medical humanitarian…

Anti-viralsAntibiotics and Infectious diseasesGlobalPharmaceutical

MRCF invests in Australian antibiotics start-up Auspherix

03-12-2013

Auspherix Pty, an early stage anti-infectives company developing novel antibiotics to treat resistant…

Antibiotics and Infectious diseasesAsia-PacificAuspherixAustraliaFinancialPharmaceuticalResearch

ProJect Pharma and TUM-spin-off link on H. pylori vaccine development

02-12-2013

Germany-based ProJect Pharmaceutics has signed a development agreement with ImevaX, a spin-off project…

Antibiotics and Infectious diseasesImevaXLicensingPharmaceuticalProJect PharmaceuticsResearchVaccines

FDA accepts priority review of Durata NDA for Dalvance

FDA accepts priority review of Durata NDA for Dalvance

27-11-2013

Shares of Durata Therapeutics leapt 13.4%, following the news that the New Drug Application for its investigational…

Antibiotics and Infectious diseasesCubicinDalvanceDurata TherapeuticsNorth AmericaPharmaceuticalRegulation

Positive top-line Ph III results with ceftolozane/tazobactam in cUTI

25-11-2013

US biopharma company Cubist Pharmaceuticals has revealed positive top-line results from its pivotal Phase…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsGenito-urinaryPharmaceuticalResearchtazobactam

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

25-11-2013

Japanese drug major Eisai (TYO: 4523) will become the Marketing Authorization Holder for the antineoplastic…

Antibiotics and Infectious diseasesAsia-PacificEisaiGliadelLicensingNobelpharmaOncologyPharmaceutical

TAC puts pressure on Janssen finalize development of TB drug bedaquiline

21-11-2013

The current standard of care for multi-drug resistant tuberculosis (MDR-TB) consists of poorly tested…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonPharmaceuticalPoliticsResearchRest of the World

AbbVie releases positive Phase III results for oral hepatitis C program

AbbVie releases positive Phase III results for oral hepatitis C program

18-11-2013

US drugmaker AbbVie has released the first Phase III results for the investigational three direct-acting-antiviral…

AbbVieAntibiotics and Infectious diseasesNorth AmericaPharmaceuticalResearchUSA

EU steps up its fight against drug-resistant bacteria

15-11-2013

A survey published by the European Commission today (November 15) reveals a decrease in antibiotic use…

Antibiotics and Infectious diseasesEuropeFinancialPharmaceuticalResearch

UK’s Helperby in deal with Cadila on ARB research and commercialization

14-11-2013

Privately-held Indian drugmaker Cadila Pharmaceuticals and UK based antibiotics discovery company, Helperby…

Antibiotics and Infectious diseasesAsia-PacificCadila PharmaceuticalsHelperby TherapeuticsMarkets & MarketingPharmaceuticalResearch

EMA publishes guidance on anti-bacterials targeted against MDR pathogens

EMA publishes guidance on anti-bacterials targeted against MDR pathogens

07-11-2013

The European Medicines Agency (EMA) has released an addendum to the guideline on the evaluation of medicinal…

Antibiotics and Infectious diseasesEuropeHealthcarePharmaceuticalRegulation

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

05-11-2013

Two units under Singapore’s Agency for Science, Technology and Research (A*STAR) have signed a joint…

A*STARAntibiotics and Infectious diseasesAstraZenecaPharmaceuticalResearch

Roche in-licenses POL7080 from Polyphor in up to 500 million-franc accord

Roche in-licenses POL7080 from Polyphor in up to 500 million-franc accord

04-11-2013

Drug major Roche has entered into an exclusive worldwide license agreement to develop and commercialize…

Antibiotics and Infectious diseasesLicensingPharmaceuticalPOL7080PolyphorRoche

High hopes for Cellceutix’ Brilacidin for serious skin infections

14-10-2013

US clinical-stage biopharmaceutical company Cellceutix says that it is completing the required documentation…

Antibiotics and Infectious diseasesbrilacidinCellceutixDermatologicalsPharmaceuticalResearch

US infectious disease specialists’ prescribing choices for GNIs

US infectious disease specialists’ prescribing choices for GNIs

09-10-2013

A majority of US surveyed infectious disease specialists are willing to prescribe novel antibiotics if…

Antibiotics and Infectious diseasesMarkets & MarketingNorth AmericaPharmaceuticalPricing

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

FDA issues new Boxed Warning on Pfizer antibacterial

FDA issues new Boxed Warning on Pfizer antibacterial

28-09-2013

The US Food and Drug Administration is warning that an additional analysis shows an increased risk of…

Antibiotics and Infectious diseasesNorth AmericaPfizerPharmaceuticalRegulationTygacil

76 to 100 of 220 results

Back to top